Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies

Myelodysplastic syndrome (MDS) is a heterogeneous hematological malignancy, characterized by cytopenia and accompanied by a risk of transformation into acute myeloid leukemia (AML). Epidemiological studies for decades have shown association between autoimmune diseases (AIDs) and MDS. Specifically, patients with antecedent AIDs tends to have an increased risk of developing MDS, and these patients display different clinical characteristics and outcomes. Importantly, immune dysregulation has been the common driving force between MDS and AIDs pathogenesis.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research